Proton therapy for early-stage non-small cell lung cancer (NSCLC)

Daniel R. Gomez, Heng Li, Joe Y. Chang

Research output: Contribution to journalReview article

Abstract

In the setting of early-stage non-small cell lung cancer (NSCLC), defining the optimal clinical context for proton beam therapy (PBT) is challenging due to the increasing evidence demonstrating high rates of local control and good tolerance of stereotactic ablative body radiation (SABR). Given the relatively small percentage of lung and other critical structures treated with SABR, dosimetric studies comparing the two techniques have typically concluded that there are modest advantages to PBT, typically by reducing the low dose volumes, such as volume of lung receiving 5 Gy. This advantage may be more significant in treating larger tumors, multiple tumors, or central tumors. Most of the published studies are based on passive scattering PBT. Dosimetric benefits are likely to increase when pencil beam scanning/intensity-modulated proton therapy (IMPT) is employed, as has been observed in dosimetric reports in the locally advanced setting. More clinical data is needed regarding the safety and efficacy of stereotactic PBT in comparison to SABR. However, the only randomized trial that has been attempted closed early due to poor accrual, thus demonstrating the difficulty in designing trials in this context that incorporate a relevant and focused scientific question that can be extrapolated to clinical practice, yet also accrue sufficiently. The advent and increased use of advanced image-guided radiation therapy (IGRT) techniques in the context of proton therapy, as well as the widespread implementation of IMPT, will increase the potential benefit of PBT. The next 5-10 years will likely yield more appropriate, feasible studies that will help answer the question of patient selection for this advanced technology.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalTranslational Lung Cancer Research
Volume7
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

Proton Therapy
Non-Small Cell Lung Carcinoma
Radiation
Image-Guided Radiotherapy
Neoplasms
Lung
Patient Selection
Technology
Safety

Keywords

  • Early stage
  • Non-small cell lung cancer (NSCLC)
  • Proton therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Proton therapy for early-stage non-small cell lung cancer (NSCLC). / Gomez, Daniel R.; Li, Heng; Chang, Joe Y.

In: Translational Lung Cancer Research, Vol. 7, No. 2, 01.04.2018, p. 199-204.

Research output: Contribution to journalReview article

Gomez, Daniel R. ; Li, Heng ; Chang, Joe Y. / Proton therapy for early-stage non-small cell lung cancer (NSCLC). In: Translational Lung Cancer Research. 2018 ; Vol. 7, No. 2. pp. 199-204.
@article{0f55bd8db8db4e40978655476b8a6b94,
title = "Proton therapy for early-stage non-small cell lung cancer (NSCLC)",
abstract = "In the setting of early-stage non-small cell lung cancer (NSCLC), defining the optimal clinical context for proton beam therapy (PBT) is challenging due to the increasing evidence demonstrating high rates of local control and good tolerance of stereotactic ablative body radiation (SABR). Given the relatively small percentage of lung and other critical structures treated with SABR, dosimetric studies comparing the two techniques have typically concluded that there are modest advantages to PBT, typically by reducing the low dose volumes, such as volume of lung receiving 5 Gy. This advantage may be more significant in treating larger tumors, multiple tumors, or central tumors. Most of the published studies are based on passive scattering PBT. Dosimetric benefits are likely to increase when pencil beam scanning/intensity-modulated proton therapy (IMPT) is employed, as has been observed in dosimetric reports in the locally advanced setting. More clinical data is needed regarding the safety and efficacy of stereotactic PBT in comparison to SABR. However, the only randomized trial that has been attempted closed early due to poor accrual, thus demonstrating the difficulty in designing trials in this context that incorporate a relevant and focused scientific question that can be extrapolated to clinical practice, yet also accrue sufficiently. The advent and increased use of advanced image-guided radiation therapy (IGRT) techniques in the context of proton therapy, as well as the widespread implementation of IMPT, will increase the potential benefit of PBT. The next 5-10 years will likely yield more appropriate, feasible studies that will help answer the question of patient selection for this advanced technology.",
keywords = "Early stage, Non-small cell lung cancer (NSCLC), Proton therapy",
author = "Gomez, {Daniel R.} and Heng Li and Chang, {Joe Y.}",
year = "2018",
month = "4",
day = "1",
doi = "10.21037/tlcr.2018.04.12",
language = "English (US)",
volume = "7",
pages = "199--204",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "2",

}

TY - JOUR

T1 - Proton therapy for early-stage non-small cell lung cancer (NSCLC)

AU - Gomez, Daniel R.

AU - Li, Heng

AU - Chang, Joe Y.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - In the setting of early-stage non-small cell lung cancer (NSCLC), defining the optimal clinical context for proton beam therapy (PBT) is challenging due to the increasing evidence demonstrating high rates of local control and good tolerance of stereotactic ablative body radiation (SABR). Given the relatively small percentage of lung and other critical structures treated with SABR, dosimetric studies comparing the two techniques have typically concluded that there are modest advantages to PBT, typically by reducing the low dose volumes, such as volume of lung receiving 5 Gy. This advantage may be more significant in treating larger tumors, multiple tumors, or central tumors. Most of the published studies are based on passive scattering PBT. Dosimetric benefits are likely to increase when pencil beam scanning/intensity-modulated proton therapy (IMPT) is employed, as has been observed in dosimetric reports in the locally advanced setting. More clinical data is needed regarding the safety and efficacy of stereotactic PBT in comparison to SABR. However, the only randomized trial that has been attempted closed early due to poor accrual, thus demonstrating the difficulty in designing trials in this context that incorporate a relevant and focused scientific question that can be extrapolated to clinical practice, yet also accrue sufficiently. The advent and increased use of advanced image-guided radiation therapy (IGRT) techniques in the context of proton therapy, as well as the widespread implementation of IMPT, will increase the potential benefit of PBT. The next 5-10 years will likely yield more appropriate, feasible studies that will help answer the question of patient selection for this advanced technology.

AB - In the setting of early-stage non-small cell lung cancer (NSCLC), defining the optimal clinical context for proton beam therapy (PBT) is challenging due to the increasing evidence demonstrating high rates of local control and good tolerance of stereotactic ablative body radiation (SABR). Given the relatively small percentage of lung and other critical structures treated with SABR, dosimetric studies comparing the two techniques have typically concluded that there are modest advantages to PBT, typically by reducing the low dose volumes, such as volume of lung receiving 5 Gy. This advantage may be more significant in treating larger tumors, multiple tumors, or central tumors. Most of the published studies are based on passive scattering PBT. Dosimetric benefits are likely to increase when pencil beam scanning/intensity-modulated proton therapy (IMPT) is employed, as has been observed in dosimetric reports in the locally advanced setting. More clinical data is needed regarding the safety and efficacy of stereotactic PBT in comparison to SABR. However, the only randomized trial that has been attempted closed early due to poor accrual, thus demonstrating the difficulty in designing trials in this context that incorporate a relevant and focused scientific question that can be extrapolated to clinical practice, yet also accrue sufficiently. The advent and increased use of advanced image-guided radiation therapy (IGRT) techniques in the context of proton therapy, as well as the widespread implementation of IMPT, will increase the potential benefit of PBT. The next 5-10 years will likely yield more appropriate, feasible studies that will help answer the question of patient selection for this advanced technology.

KW - Early stage

KW - Non-small cell lung cancer (NSCLC)

KW - Proton therapy

UR - http://www.scopus.com/inward/record.url?scp=85046949982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046949982&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2018.04.12

DO - 10.21037/tlcr.2018.04.12

M3 - Review article

VL - 7

SP - 199

EP - 204

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 2

ER -